Skin & Hair

Melanotan I

Also known as: Afamelanotide, Scenesse, MT-1, CUV1647

FDA Approved
Share:

Key Facts: Melanotan I

Category
Skin & Hair
FDA Status
FDA Approved
Clinical Status
FDA Approved (2019) - Erythropoietic Protoporphyria
Administration
Subcutaneous implant (not injection)
Typical Dose
500-1000 mcg daily (loading), then 500-1000 mcg 1-2x weekly (maintenance)
Frequency
Daily during loading (1-2 weeks), then 1-2x weekly maintenance
Duration
Long-term / as needed before sun season
Also Known As
Afamelanotide, Scenesse, MT-1, CUV1647

Mechanism of Action

Afamelanotide binds and activates the melanocortin-1 receptor (MC1R) on pigment-producing melanocytes, driving production of eumelanin, the dark, photoprotective form of melanin. Two amino acid swaps from natural alpha-MSH - norleucine at position 4 and D-phenylalanine at position 7 - make it bind MC1R more tightly and resist breakdown, so it lasts far longer and acts more potently than the native hormone. The extra eumelanin absorbs and scatters light and also brings antioxidant and DNA-repair-supporting effects, which is why it raises the light dose EPP patients can tolerate before pain hits. Unlike Melanotan II, it is selective enough toward MC1R that it is not primarily a sexual-function or appetite agent.

Research Summary

This is one of the few peptides on this list with gold-standard human evidence. The pivotal data came from two multicenter, randomized, double-blind, placebo-controlled trials published in the New England Journal of Medicine in 2015 (Langendonk et al., 373(1):48-59), enrolling 168 EPP patients across the EU and US who received the 16 mg implant or placebo every 60 days. Afamelanotide significantly increased pain-free time in sunlight (for example, median 69.4 vs 40.8 hours in the US trial), reduced phototoxic reactions, and improved disease-specific quality of life, with mostly mild adverse events. Long-term observational follow-up of EPP patients has supported continued benefit and an acceptable safety profile. The big caveats: this approval is narrowly for EPP, not for cosmetic tanning, and the unregulated injectable 'Melanotan' products people buy online are not the same controlled, clinician-administered implant and carry real risks. Bottom line: a genuinely proven, approved drug for a rare condition, frequently misused outside that lane.

Trial Progress:FDA Approved
Pre
I
II
III
IV
FDA

Dosing Information

FDA Approved·Human clinical trials completed, FDA approved

Typical Dosing

Community experience

Common Dose

500-1000 mcg daily (loading), then 500-1000 mcg 1-2x weekly (maintenance)

Range

250-1000 mcg per injection

Frequency

Daily during loading (1-2 weeks), then 1-2x weekly maintenance

Injected subcutaneously like MT-II. More selective than MT-II with fewer sexual side effects. Slower onset of tanning than MT-II. FDA version (Scenesse) is an implant for EPP patients only.

Research Dosing

Scientific studies

FDA-approved dosing for EPP

Doses from Studies

Duration

Long-term / as needed before sun season

Administration

Subcutaneous implant (not injection)

Timing & Administration

Best Time to Take

Evening or before sun exposure

Daily during loading, then maintenance doses

Food Recommendation

With or without food

Why This Timing?

Similar to MT-II, evening use minimizes visible flushing. Pre-sun exposure maximizes tanning effect.

Possible Side Effects

Not everyone experiences these effects. Individual responses vary based on dosage, duration, and personal factors.

  • Nausea (common)
  • Skin darkening (intended effect)
  • Headache
  • Fatigue
  • Injection site reactions
  • FDA approved with known safety profile

References

Research This Peptide Further

Frequently Asked Questions

What does Melanotan I do?

Melanotan I is the research name for afamelanotide, a 13-amino-acid synthetic analog of alpha-melanocyte-stimulating hormone (alpha-MSH), also written as [Nle4, D-Phe7]-alpha-MSH or NDP-MSH. It is the only melanocortin peptide with regulatory approval: sold as Scenesse, it was approved by the EMA in 2014 and the FDA in 2019 to increase pain-free light exposure in adults with erythropoietic protoporphyria (EPP). It is given as a 16 mg bioresorbable implant under the skin by a clinician, not as a tanning shortcut.

How does Melanotan I work?

Afamelanotide binds and activates the melanocortin-1 receptor (MC1R) on pigment-producing melanocytes, driving production of eumelanin, the dark, photoprotective form of melanin. Two amino acid swaps from natural alpha-MSH - norleucine at position 4 and D-phenylalanine at position 7 - make it bind MC1R more tightly and resist breakdown, so it lasts far longer and acts more potently than the native hormone. The extra eumelanin absorbs and scatters light and also brings antioxidant and DNA-repair-supporting effects, which is why it raises the light dose EPP patients can tolerate before pain hits. Unlike Melanotan II, it is selective enough toward MC1R that it is not primarily a sexual-function or appetite agent.

Is Melanotan I FDA approved?

Yes, Melanotan I is FDA approved. FDA Approved (2019) - Erythropoietic Protoporphyria

What are the side effects of Melanotan I?

Reported side effects include: Nausea (common), Skin darkening (intended effect), Headache, Fatigue, Injection site reactions. Individual responses vary based on dosage, duration, and personal health factors.

What is the typical dose of Melanotan I?

Community-reported common dose: 500-1000 mcg daily (loading), then 500-1000 mcg 1-2x weekly (maintenance) (Daily during loading (1-2 weeks), then 1-2x weekly maintenance). Range: 250-1000 mcg per injection. Administration: Subcutaneous implant (not injection). Community-reported doses. Not medical advice. Consult healthcare provider.

Related Peptides

Peptides commonly compared with Melanotan I or used in similar applications.

GHK-Cu

Clinical Trials

GHK-Cu is the copper(II) complex of GHK, a naturally occurring human tripeptide (glycyl-L-histidyl-L-lysine) found in blood plasma, saliva and urine, whose levels decline with age. It is researched and widely used in cosmetic skincare for skin regeneration, wound healing, collagen support and anti-aging. It is not an FDA-approved drug; it appears in over-the-counter cosmetics and as a research or compounded peptide, with most human evidence coming from small topical-skincare studies.

Skin & Hair

Snap-8

Research

SNAP-8 (Acetyl Octapeptide-3) is a synthetic eight-amino-acid topical cosmetic peptide, an extended cousin of Argireline that adds two residues to the same SNAP-25 mimic sequence. It is marketed as a needle-free way to soften expression lines, especially on the forehead and around the eyes. It is a cosmetic ingredient, not an approved drug, and the human evidence behind it is thin and mostly comes from the manufacturer.

Skin & Hair

Argireline

Research

Argireline is the trade name for acetyl hexapeptide-8 (sequence Ac-Glu-Glu-Met-Gln-Arg-Arg-NH2, also called acetyl hexapeptide-3), a synthetic peptide sold in anti-aging creams as a topical, needle-free alternative to Botox. It is designed to relax the muscle contractions behind expression lines. It is a cosmetic ingredient, not an FDA-approved drug, and the human efficacy data are genuinely mixed rather than settled.

Skin & Hair

Matrixyl

Research

Matrixyl is the trade name (Sederma) for palmitoyl pentapeptide-4, also written Pal-KTTKS, a collagen-fragment peptide attached to a fatty acid so it can cross skin. Unlike Botox-mimic peptides, it does not touch muscle: it signals skin cells to rebuild collagen, so it is aimed at fine lines, firmness and skin texture rather than expression wrinkles. It is a cosmetic ingredient with one of the better-documented topical studies in the peptide space, though far short of drug-grade proof.

Skin & Hair

Matrixyl 3000

Research

Matrixyl 3000 is Sederma's follow-up to the original Matrixyl, a fixed pair of two fatty-acid-tagged peptides: palmitoyl tripeptide-1 (Pal-GHK) and palmitoyl tetrapeptide-7 (Pal-GQPR). The idea is a one-two punch: one peptide tells skin to rebuild collagen, the other calms the low-grade inflammation that wears collagen down. It is a cosmetic ingredient aimed at firmness, fine lines and aging skin, with supportive but mostly company-generated evidence.

Skin & Hair

Copper Peptide AHK-Cu

Research

AHK-Cu is a synthetic copper-bound tripeptide, alanine-histidine-lysine complexed with a copper ion, engineered mainly for hair and scalp products. It is the lesser-known sibling of the naturally occurring GHK-Cu copper peptide, designed in the lab specifically to push hair follicles to keep growing. It is a cosmetic and research ingredient, not an approved hair-loss drug, and its evidence is essentially limited to one notable lab study.

Skin & Hair

Want updates on Melanotan I research?

Subscribe to get notified when we add new research findings, protocol updates, and related peptide information.